Open AccessHumanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform
Author(s) -
Huamao Mark Lin,
Xiaotian Pan,
Alyssa Biller,
Kyla J Covey,
Hui Huang,
Rebecca Sugarman,
Federica Scipione,
Howard West
Publication year - 2021
Publication title -
lung cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1974
pISSN - 1758-1966
DOI - 10.2217/lmt-2020-0018
Subject(s) - anaplastic lymphoma kinase , medicine , lung cancer , quality of life (healthcare) , oncology , disease , alk inhibitor , cancer , crizotinib , nursing , malignant pleural effusion
Aim: Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network. Patients & methods: Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC. Results: Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment. Conclusion: ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.